Human medicines European public assessment report (EPAR): Naglazyme, galsulfase, Mucopolysaccharidosis VI, Date of au...

Human medicines European public assessment report (EPAR): Naglazyme, galsulfase, Mucopolysaccharidosis VI, Date of authorisation: 23/01/2006, Revision: 19, Status: Authorised Human medicines European public assessment report (EPAR): Naglazyme, galsulfase, Mucopolysaccharidosis VI, Date of authorisation: 23/01/2006, Revision: 19, Status: Authorised Interview Kansrijke Start – Kansrijke Start in Meppel Ondersteuning bieden aan zwangeren in een kwetsbare omgeving. Antidota DOAC's Medicijngroep ECDC and EMA update recommendations on additional booster doses of COVID-19 vaccines The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) are recommending that second booster doses of COVID-19 vaccines be considered for people between 60 and 79 years old and people with medical conditions putting them at high risk of severe disease. Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have updated public health recommendations on the use of additional booster doses of COVID-19 vaccines this summer and in the upcoming autumn and winter seasons.

Actueel zorgnieuws in jouw mailbox ontvangen?

Direct het hele artikel lezen? Meld je aan voor de nieuwsbrief.